Relugolix and Sodium Phosphate: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Sodium Phosphate
Relugolix
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let me explain this one simply. Relugolix (Orgovyx) is a prostate cancer treatment that can, in some people, affect the heart's electrical rhythm by stretching out what's called the QT interval. Sodium phosphate is a strong bowel-cleaning prep, often used before a colonoscopy. Its concern is different: it can shift your body's salts (like potassium and magnesium), and low levels of those can also affect the heart rhythm.
Put together, there's a possible added strain on your heart's rhythm. This is a theoretical concern, not something proven, but it's worth taking seriously. Please don't change anything on your own. Your care team can check your electrolytes and heart tracing and keep this safe.
Effect: Potential additive QT prolongation. Direction/mechanism: Relugolix (GnRH antagonist) may prolong QT via androgen deprivation. Sodium phosphate bowel prep can precipitate electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) that independently favor QT prolongation, compounding risk.
- Evidence: Theoretical; severity rated major.
- Onset: Unspecified.
- At-risk patients: Congenital long QT, CHF, frequent electrolyte abnormalities, other QT-prolonging drugs.
- Management: Avoid combination where possible. If required, correct/avoid electrolyte abnormalities and consider periodic ECG and electrolyte monitoring. Neither agent is a prodrug; interaction is PD-additive, not PK-mediated.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
When relugolix is given together with medications that prolong the QT interval, the effects on the QT interval are additive. The androgen deprivation produced by GnRH agonists and antagonists can itself lengthen the QT interval. In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte disturbances, as well as those receiving drugs recognized to prolong the QT interval, weigh whether the advantages of androgen deprivation therapy such as relugolix outweigh the possible risks 1. Where feasible, do not use relugolix alongside QT prolonging agents. When such combined use cannot be avoided, refrain from using drugs that produce electrolyte disturbances (that is, hypokalemia or hypomagnesemia) 2, correct any electrolyte disturbances, and consider periodic monitoring of ECGs and electrolytes 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Keep taking both exactly as prescribed unless your care team tells you otherwise. Here is what a team usually does with this pairing:
- Weigh the need: They consider whether the bowel prep is worth using given your heart history (especially long QT syndrome, heart failure, or recurring electrolyte problems).
- Protect your salts: Because sodium phosphate can drop potassium and magnesium, they may check and correct these before and after.
- Monitor: They may run periodic ECGs and electrolyte labs.
Tell your pharmacist or prescriber you take relugolix before any colonoscopy prep, and report palpitations, fainting, or dizziness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) A study assessed male patients undergoing androgen deprivation therapy (ADT) using individual case safety reports from VigiBase, the international pharmacovigilance database, and found 184 cases of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% fatal cases), along with 99 cases of sudden death linked to ADT. The majority of aLQTS/TdP cases (62%) and sudden death cases (88%) associated with ADT arose without exposure to other agents recognized to elevate TdP risk; nevertheless, exposure to 1 drug and to 2 or more drugs carrying conditional, possible, or known TdP risk was documented in some aLQTS/TdP (23% or 43%) and sudden death (18% and 22%) events. The agents regarded as ADTs included abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism. Among the 10 ADTs assessed, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The patients had a median age of roughly 76 years, and the median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. Patients were primarily receiving ADT for prostate cancer, with some being treated for prostatism and androgenic alopecia. Most patients were on ADT monotherapy (83%); 17% were receiving ADT combination therapy 3.
Common questions
Can I take Relugolix and Sodium Phosphate together?
Sodium phosphate can lower key electrolytes and add to relugolix's effect on heart rhythm, so avoid the combo when possible; if both are needed, let your team correct electrolytes and monitor your ECG. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Relugolix and Sodium Phosphate interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Relugolix and Sodium Phosphate interaction managed?
Keep taking both exactly as prescribed unless your care team tells you otherwise. Here is what a team usually does with this pairing: Weigh the need: They consider whether the bowel prep is worth using given your heart history (especially long QT syndrome, heart failure, or recurring electrolyte problems). Protect your salts: Because sodium phosphate can drop potassium and magnesium, they may chec… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Relugolix or Sodium Phosphate need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Keep reading about Sodium Phosphate
Keep reading about Relugolix
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist